Pharma BD Deal Intelligence

Pfizer Inc. / Excaliard Pharmaceuticals, Inc.

2011 · Acquisition/Merger · Complete

Announcement Sentiment

Strongly positive

Pfizer acquired Excaliard for undisclosed upfront plus contingent payments. Isis (now Ionis) entitled to up to $14M as a former licensor. Deal added EXC-001 antisense fibrosis candidate to Pfizer pipeline. Below clear $250M threshold per public terms but strategically notable platform deal.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Terminated

Assessment window: 10yr post-close.

Key facts

Announced Nov 22, 2011
Closed Dec 02, 2011
Deal type Acquisition/Merger
Therapeutic area Skin fibrosis / scarring
Indications Skin fibrosis / scarring
Key assets EXC-001 (antisense oligonucleotide targeting CTGF)
Mechanism Antisense oligonucleotide inhibiting connective tissue growth factor (CTGF/CCN2) expression

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals